Genomic research is transforming healthcare by providing deep insights into the genetic factors that contribute to disease. We conduct a wide range of studies at the intersection of genomics and the economics of population health, to understand the economic implications of genomic technologies and to evaluate interventions that incorporate genomic information into healthcare decision-making.

An important area of research involves exploring the use of genomic sequencing in healthy populations, such as adults and newborn babies. This includes determining the outcomes that matter most to patients and families when undergoing sequencing.

Our researchers assess the cost-effectiveness of implementing widespread genomic screening, considering not only the financial costs but also the ethical, legal, and social implications. This work helps inform policies on how genomic information can be integrated into routine healthcare to improve disease prevention, diagnosis, and treatment.

Another focus is on the economic implications of using polygenic risk scores to guide patient care. Polygenic risk scores quantify an individual's genetic susceptibility to certain diseases based on the presence of multiple genetic variants. We evaluate how these scores can be used cost-effectively to personalise prevention strategies and treatments, potentially leading to better health outcomes and more efficient use of healthcare resources.

Modelling genomic approaches presents unique challenges due to the complexity of genetic data and the need for sophisticated analytical methods. Our researchers develop and refine health economic models that accurately capture the costs and benefits associated with genomic technologies. They utilise innovative approaches like Mendelian randomisation studies to estimate causal relationships and inform cost-effectiveness analyses, which can guide decision-making in healthcare policy and practice.

Funding mechanisms for genomic technologies are also a critical area of study. We examine how healthcare systems can sustainably finance the integration of genomics into patient care. This includes analysing different funding models, reimbursement strategies, and the long-term economic impacts of adopting genomic innovations.